AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Akari Therapeutics Plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.89+1.71 (+20.90%)
Close on Oct 19, 2026
- Market cap
- $1.42T
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$22.11 (−69.09%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.42T
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 76225.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$30.96M
- EPS, diluted
- $0.00
- Book value per share
- $0.00
- Diluted shares
- 143.32B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$30.99M
Net income
-$30.96M
EPS, diluted
$0.00
Free cash flow
–
Reported periodTrailing twelve months